Researchers find 9 cannabinoids that might protect the brain against toxicities associated with aging. These non-intoxicating cannabinoids are potential drug candidates for Alzheimer’s Disease, and they might also be options for other neurodegenerative diseases, too
View this review (yellow link) or download:
This paper is also stored here: http://bit.ly/2L9GccX inside the CED Foundation Archive
To explore related information, click the keywords below:
Efficacy and safety of cannabidiol followed by an open-label add-on of tetrahydrocannabinol for the treatment of chronic pain in patients with rheumatoid arthritis or ankylosing spondylitis: protocol for a multicentre, randomized, placebo-controlled study
Current researchers have proposed a study protocol that would expose any possible benefits of cannabidiol (CBD) and tetrahydrocannabinol (THC) for the treatment of chronic pain in patients suffering from rheumatoid arthritis (RA) and ankylosing spondylitis (AS). This new study hopes to identify how medical cannabis affects pain and cognitive function in RA and AS and provide evidence that cannabis-based pain medication is an alternative to opioids with fewer risks.
This paper is also stored here: http://bit.ly/2Fb08s5 inside the CED Foundation Archive
To explore related information, click the keywords below:
Training and Practices of Cannabis Dispensary Staff
How much medical training does your local budtender possess? An online survey sent to medical marijuana dispensary staff reported only 55% of staffers had any formal training for their position, with 20% reporting some background in medical/scientific training. The analysis reported that many among the dispensary staff are recommending cannabis choices that are consistent with current evidence, but some are recommending strains that are either ineffective or exacerbate a patient’s condition. The findings of this study stress the importance of consistent and well-regulated training of dispensary staff.
View this review (yellow link) or download:
This paper is also stored here: http://bit.ly/2FfJNSC inside the CED Foundation Archive
To explore related information, click the keywords below:
View this review (yellow link) or download:
This paper is also stored here: http://bit.ly/2l4sexZ inside the CED Foundation Archive
To explore related information, click the keywords below:
Pharmaceutical Cannabis Derivatives Help Discover their Receptors and Functions for Autoimmune Illnesses
A recent study conducted by Michigan State University exposed the potential for cannabinoid receptor 2 (CB2) to target the treatment of inflammatory conditions. Elevated levels of plasmacytoid dendritic cells (pCD, a type of cell in the immune system) contribute to chronic inflammation in autoimmune diseases, such as Rheumatoid Arthritis. Researchers found that synthetic CB2 agonists reported comparable benefits to THC, but minimized the cerebral effects as the psychotropic activity is mediated by cannabinoid receptor 1 (CB1). This evidence demonstrates the potential benefits of CB2-targeted treatment for inflammatory conditions. Unfortunately, there are serious concerns about the misuse of some synthetic cannabinoids, so there is still a missing bridge, in products and public education, between these research products and potential therapeutic pharmaceuticals, down the road.
View this review (yellow link) or download:
This paper is also stored here: http://bit.ly/2HZ6cWb inside the CED Foundation Archive
To explore related information, click keywords:
Because of the associated anti-inflammatory action, modulation of CB1R & CB2R is helpful to treat autoimmune diseases, including Multiple Sclerosis, Type-1 Diabetes Mellitus, and Rheumatoid Arthritis The full list is truly very much longer, as every illness necessarily involves the immune system and cellular communication.
The following review, written by Elaine D. Gonc ̧alves
The following review, written by Daphna Katz-Talmor: (yes, same name, unfortunately!)
In a study of 40 mice, scientists find that the CB2-selective agonist significantly reduced the severity of arthritis and markedly reduced bone erosion. These data clearly indicate that the CB2-selective agonist may be considered a novel treatment for rheumatoid arthritis.
